Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Imugene ( (AU:IMU) ).
Imugene Limited has issued 1,736,111 fully paid ordinary shares to CVI Investment Inc. following the conversion of five zero coupon convertible notes, increasing its share capital without undertaking a separate disclosure to investors under the fundraising provisions of the Corporations Act. The company confirmed it remains compliant with its financial reporting and continuous disclosure obligations and stated there is no excluded information requiring disclosure, signalling a routine capital structure adjustment rather than a change in strategic direction, but one that modestly dilutes existing shareholders while converting debt-like instruments into equity.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company developing novel immunotherapies designed to activate cancer patients’ immune systems to treat and eradicate tumours. Its pipeline includes the off-the-shelf allogeneic CAR T cell therapy azer-cel targeting CD19 for blood cancers, alongside oncolytic virotherapy candidates (onCARlytics) intended for use with standard-of-care drugs and emerging immunotherapies for a range of solid and liquid tumours, supported by an international team of cancer experts.
Average Trading Volume: 1,335,029
Technical Sentiment Signal: Sell
Current Market Cap: A$102.3M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.